What Is Your Prostate Understanding Its Role Health And Diagnostics

Published

Table of Contents

The prostate—a small but critically influential gland in the male reproductive system—plays a pivotal role in urinary function, semen production, and overall male health. Positioned just below the bladder and surrounding the urethra, this walnut-sized organ secretes essential fluids that nourish and transport sperm while maintaining pH balance and enzymatic activity. Yet, its significance extends beyond reproduction, as prostate health directly impacts urinary control, quality of life, and long-term well-being. From benign enlargement to life-threatening cancers, conditions affecting the prostate demand early recognition, precise diagnostics, and evidence-based interventions.

This exploration delves into the prostate’s anatomical intricacies, its functional interplay with surrounding structures, and the evolutionary adaptations that distinguish it across species. It further examines the spectrum of prostate disorders—ranging from common benign hyperplasia to rare inflammatory conditions—and outlines systematic diagnostic approaches, from digital rectal exams to advanced imaging. By synthesizing clinical insights with patient-centered strategies, this guide equips readers with a comprehensive understanding of prostate health, empowering informed decision-making and proactive care.

what is your prostate

Anatomy and Function of the Prostate

The prostate gland is a critical component of the male reproductive system, situated inferior to the urinary bladder and surrounding the proximal urethra. Its dual role in urinary continence and semen production underscores its physiological significance, while its anatomical positioning influences clinical conditions such as benign prostatic hyperplasia (BPH) and prostate cancer. Understanding its structure—including glandular, stromal, and epithelial tissue composition—reveals how cellular interactions regulate secretion, motility, and systemic health. Comparative anatomical studies further highlight evolutionary adaptations across species, offering insights into functional conservation and divergence.

The prostate’s location, size, and functional interactions with adjacent structures define its role in male physiology. Positioned directly inferior to the bladder neck and encircling the urethra, it measures approximately 20–40 grams in healthy adults, with dimensions expanding during adolescence and gradually enlarging with age. Its strategic placement ensures it contributes to both urinary and reproductive functions, though pathological changes—such as hypertrophy or inflammation—can disrupt these systems.

Prostate Location and Relationship with Adjacent Structures

The prostate’s anatomical positioning is integral to its physiological functions. Below is a structured breakdown of its spatial and functional relationships with surrounding organs and systems, formatted for clarity:
Organ/System Proximity to Prostate Functional Interaction Clinical Relevance
Urinary Bladder Directly superior; separated by the bladder neck Regulates urine flow via urethral compression during ejaculation; prevents retrograde ejaculation BPH obstruction risk; urinary retention or incontinence due to prostate enlargement
Urethra (Prostatic Urethra) Surrounds the urethra along its proximal segment Secretes alkaline fluid to neutralize vaginal acidity; facilitates sperm motility Obstructive symptoms (hesitancy, weak stream) in BPH; urethral strictures post-prostatectomy
Seminal Vesicles Posterior and lateral; ducts converge at the ejaculatory ducts Combines prostatic fluid with seminal vesicle secretions (fructose, prostaglandins) to form semen Infertility or oligospermia if ductal obstruction occurs
Pelvic Floor Muscles (Levator Ani) Inferior and posterior support Stabilizes prostate position; aids in urinary and ejaculatory control Pelvic floor dysfunction post-radical prostatectomy; stress incontinence
Neurovascular Bundle Lateral (posterolateral in humans) Innervates erectile tissue; autonomic control of prostate secretion Erectile dysfunction or urinary incontinence post-surgical nerve damage
Key Insight: The prostate’s proximity to the urethra and bladder neck makes it susceptible to obstructive pathologies, while its secretory role in semen production is contingent on coordinated interactions with the seminal vesicles and vas deferens.

Prostate Tissue Composition and Cellular Functions

The prostate’s functional heterogeneity stems from its distinct tissue layers: glandular epithelium, stromal cells, and basement membrane. Each component contributes uniquely to secretion, structural integrity, and pathological susceptibility.

- Glandular Epithelium (Acini):
Composed of luminal epithelial cells (secreting prostate-specific antigen [PSA] and prostatic acid phosphatase) and basal cells (stem cell niche for regeneration). The columnar luminal cells produce ~20–30% of semen volume, rich in zinc (antimicrobial), citrate (energy substrate), and prostate-specific antigens (PSA, liquefies semen).

- Stromal Tissue:
Includes fibromuscular stroma (smooth muscle and collagen) regulating glandular compression during ejaculation, and fibroblasts secreting extracellular matrix proteins. Stromal-epithelial interactions modulate growth factors (e.g., androgens, TGF-β), influencing both normal development and hyperplasia/carcinoma progression.

- Basement Membrane:
A lamina propria separating epithelium from stroma, providing structural support and a barrier against metastatic invasion. Disruption here is linked to prostate cancer invasion.

Blockquote:
"The prostate’s glandular epithelium is the primary site of secretory activity, while stromal cells orchestrate mechanical and hormonal regulation—disruptions in either can lead to clinical pathologies ranging from BPH to adenocarcinoma."

Prostate Secretions and Semen Composition

Prostatic fluid constitutes 20–30% of ejaculate volume, with a pH of 6.5–7.5 (alkaline to counteract vaginal acidity). Its biochemical composition includes:

- Enzymes:

  • PSA (Prostate-Specific Antigen): Cleaves semenogelins to liquefy coagulated semen post-ejaculation.
  • Prostatic Acid Phosphatase (PAP): Hydrolyzes phosphate esters; elevated levels historically used as a cancer marker (though PSA is now standard).

    • - Nutrients and Ions:

  • Zinc (1.5–3.5 mg/mL): Acts as an antimicrobial agent and stabilizes membrane integrity.
  • Citrate (50–100 mM): Provides energy for sperm motility via the Krebs cycle.
  • Calcium, Magnesium, Potassium: Regulate osmotic balance and enzymatic activity.

    • - Other Components:

  • Semenogelins: Form the coagulum of semen.
  • Prostaglandins (PGE₂): Stimulate uterine contractions to aid sperm transport.

    • Functional Outcome:
    The prostate’s secretions neutralize acidity, enhance sperm viability, and facilitate semen liquefaction, ensuring optimal conditions for fertilization. Disruptions in secretion (e.g., due to androgen deprivation or obstructive pathologies) impair reproductive efficiency.

    Comparative Anatomy: Human Prostate vs. Other Mammals

    Prostate morphology varies significantly across species, reflecting evolutionary adaptations tied to reproductive strategies, dietary habits, and mating systems. Below is a comparative analysis of key structural and functional differences:

    what is your prostate - Ilustrasi 2

    Common Prostate Conditions and Symptoms

    Benign prostatic hyperplasia (BPH), prostatitis, prostate cancer, and chronic pelvic pain syndrome (CPPS) represent the most frequently encountered prostate-related conditions in clinical practice. These conditions vary significantly in etiology, symptom presentation, and management approaches, necessitating a structured understanding of their prevalence, risk factors, and diagnostic distinctions. While BPH and prostate cancer often dominate discussions due to their age-related prevalence, lesser-known conditions such as granulomatous prostatitis or prostate stones may present diagnostic challenges that require specialized evaluation. This section explores the clinical manifestations, underlying mechanisms, and differential diagnostic strategies for these conditions, emphasizing early recognition to optimize patient outcomes.

    Benign Prostatic Hyperplasia (BPH) and Its Distinction from Prostate Cancer

    Benign prostatic hyperplasia (BPH) is the most common lower urinary tract symptom (LUTS) in aging males, characterized by the non-cancerous enlargement of the prostate gland. Its prevalence increases with age, affecting approximately 40% of men aged 50–59 years, 50% of men aged 60–69 years, and 90% of men older than 80 years (Urology Care Foundation, 2023). Unlike prostate cancer, BPH does not metastasize or pose a direct threat to life but significantly impairs quality of life due to urinary symptoms.

    Key Risk Factors for BPH:

  • Age: The primary determinant, with incidence rising after 40 years.
  • Genetics: Family history of BPH increases risk by 2–3 times.
  • Obesity: Body mass index (BMI) ≥ 30 correlates with a 40% higher risk of moderate-to-severe BPH (European Association of Urology, 2022).
  • Dietary Factors:
  • High-fat diets (particularly saturated fats) are associated with a 25% increased risk (Journal of Urology, 2021).
  • Low intake of fruits/vegetables (deficient in antioxidants) may exacerbate oxidative stress in prostate tissue.
  • Caffeine and alcohol contribute to bladder irritability, worsening LUTS.
  • Metabolic Syndrome: Diabetes and hypertension are linked to BPH progression via endothelial dysfunction.

    • Differential Diagnosis: BPH vs. Prostate Cancer
    While both conditions may present with urinary symptoms, prostate cancer typically involves asymptomatic early stages or systemic symptoms (e.g., bone pain, weight loss) in advanced cases. Key distinctions include:

  • Digital Rectal Exam (DRE): BPH presents as a smooth, symmetrically enlarged prostate, whereas cancer may reveal hard, irregular nodules.
  • Prostate-Specific Antigen (PSA): Elevated PSA (>4 ng/mL) warrants further investigation for cancer, though BPH alone can also elevate PSA.
  • Imaging: Transrectal ultrasound (TRUS) or MRI may differentiate between homogeneous BPH enlargement and heterogeneous cancerous lesions.

    • Early Symptom Checklist for Prostate Conditions

    Prostate-related conditions often share overlapping symptoms, complicating early diagnosis. Below is a structured checklist to aid clinicians in identifying red flags and prioritizing interventions. Severity is graded on a scale of 1 (mild) to 5 (urgent medical attention required).
    Feature Humans Canines (Dogs) Rodents (Rats/Mice) Evolutionary Adaptation
    Prostate Zones Peripheral (70%), Central, Transition, Fibromuscular Dorsal, Lateral, Proximal (homologous to human zones) Dorsolateral and Ventrolateral lobes (simpler structure) Humans exhibit zone-specific cancer predisposition (peripheral zone most common); rodents lack distinct zones, correlating with lower spontaneous carcinoma rates.
    Relative Size 20–40 g (enlarges with age) 5–10 g (stable size); larger in breeds with high testosterone (e.g., German Shepherds) 0.1–0.5 g (minimal age-related growth) Canine prostates are proportionally larger due to scent-marking behaviors requiring higher seminal fluid volume; rodents have smaller prostates linked to shorter mating cycles.
    Secretory Focus Alkaline fluid (pH 6.5–7.5); high zinc/citrate Mucin-rich; lower pH (~6.0) to resist vaginal pathogens in canids Proteinaceous; high in prostatein (antimicrobial peptide) Humans prioritize sperm protection; canines emphasize pathogen resistance; rodents focus on rapid sperm clearance post-mating.
    Pathological Susceptibility
    Symptom Condition Severity Scale (1–5)
    Weak or intermittent urine stream BPH 2–4 (worsens with progression)
    Urinary urgency or frequency (especially nocturia) BPH, Overactive Bladder (OAB) 2–5 (nocturia ≥2 times/night = severity 4)
    Hesitancy or straining to initiate urination BPH, Prostatitis 3–5 (acute retention = severity 5)
    Dysuria (painful urination) Prostatitis, UTI, Prostate Cancer (advanced) 3–5 (fever + dysuria = severity 5)
    Hematuria (blood in urine) Prostate Cancer, Bladder Cancer, BPH complications 4–5 (gross hematuria = severity 5)
    Perineal or suprapubic pain Chronic Pelvic Pain Syndrome (CPPS), Prostatitis 2–4 (persistent pain >3 months = severity 3)
    Erectile dysfunction (ED) BPH (vascular compression), Prostate Cancer treatment side effect 2–3 (unless acute onset)
    Bone pain or unexplained weight loss Prostate Cancer (metastatic) 5 (immediate referral)
    Recurrent urinary tract infections (UTIs) BPH (urinary stasis), Prostatitis 3–4 (fever + UTI = severity 4)
    Note: Symptoms may overlap, and severity escalation (e.g., acute retention, hematuria) necessitates immediate urological evaluation.

    Chronic Pelvic Pain Syndrome (CPPS) and Its Pathophysiological Subtypes

    Chronic pelvic pain syndrome (CPPS) is characterized by persistent (≥3 months) pelvic pain in the absence of urinary tract infection or other identifiable causes. It accounts for 15–20% of urology outpatient visits and significantly impacts quality of life (NIH Chronic Prostatitis Symptom Index, 2020). CPPS is classified into two subtypes based on inflammatory markers:

    1. Inflammatory CPPS (Category IIIA)

  • Mechanism: Chronic inflammation due to prostatic ductal obstruction, autoimmune responses, or bacterial persistence (e.g., E. coli, Chlamydia).
  • Pathophysiology:
  • Neurogenic inflammation: Release of substance P and nerve growth factor (NGF) sensitizes pelvic nerves.
  • Oxidative stress: Reactive oxygen species (ROS) damage prostate epithelial cells, triggering cytokine release (IL-6, TNF-α).
  • Diagnostic Clues: Elevated leukocytes in expressed prostatic secretions (EPS) or post-massage urine.

    • 2. Non-Inflammatory CPPS (Category IIIB)

  • Mechanism: Likely multifactorial, involving pelvic floor muscle dysfunction, visceral hypersensitivity, or central nervous system sensitization.
  • Pathophysiology:
  • Myofascial trigger points: Hypertonic pelvic floor muscles compress nerves (e.g., pudendal nerve).
  • Neuroplastic changes: Altered pain processing in the thalamus and anterior cingulate cortex (fMRI studies).
  • Psychosocial factors: Anxiety/depression may amplify pain perception via descending inhibitory pathways.

    • Diagnostic Challenges:

  • Overlap with other conditions: Mimics prostatitis, interstitial cystitis, or irritable bowel syndrome (IBS).
  • Lack of biomarkers: No single test confirms CPPS; diagnosis is exclusionary after ruling out infections, stones, or cancer.
  • Subjective pain assessment: Reliance on visual analog scales (VAS) or NIH-CPSI questionnaires introduces variability.

    • Lesser-Known Prostate Conditions and Diagnostic Challenges

    Beyond BPH and cancer, several rare prostate conditions pose diagnostic dilemmas due to nonspecific symptoms or atypical presentations. Below are five underrecognized entities and their clinical hurdles:

    1. Prostate Stones (Calculi)

  • Etiology: Chronic inflammation (e.g., CPPS) or metabolic disorders (e.g., hypercalcemia) precipitate calcium phosphate or struvite stones.
  • Diagnostic Challenge:
  • Asymptomatic in 30% of cases; symptoms include dysuria, hematuria, or perineal pain.
  • Imaging: TRUS or CT may miss small stones (<3 mm); MRI with diffusion-weighted imaging (DWI) is

    • what is your prostate - Ilustrasi 3

    Diagnostic Methods and Procedures for Prostate Evaluation

    Prostate-related disorders, including benign prostatic hyperplasia (BPH) and prostate cancer, require precise diagnostic approaches to ensure accurate staging, risk stratification, and treatment planning. Diagnostic techniques range from minimally invasive screening tools, such as the digital rectal exam (DRE) and prostate-specific antigen (PSA) testing, to advanced imaging modalities like multiparametric MRI (mpMRI) and targeted biopsy procedures. Each method serves distinct clinical purposes—from initial suspicion of pathology to definitive diagnosis—while balancing factors such as invasiveness, cost, and diagnostic yield. Below is a structured overview of key diagnostic procedures, their technical execution, and comparative efficacy in identifying prostate conditions.

    Digital Rectal Examination (DRE) Process and Findings

    The digital rectal examination (DRE) is a foundational diagnostic tool used to assess prostate size, texture, and symmetry through manual palpation. This procedure is typically performed during a routine physical examination and provides critical tactile information that may indicate abnormalities such as nodules, induration, or asymmetry—hallmarks of potential malignancy or BPH.

    Patient Preparation and Procedure Execution
    Prior to the DRE, patients are instructed to empty their bladder to minimize discomfort and ensure optimal examination conditions. The examiner, wearing a lubricated, gloved index finger, inserts it gently into the rectum while applying light pressure to the anterior rectal wall, where the prostate lies. The prostate’s surface is evaluated for:

  • Size: Enlargement may suggest BPH, while asymmetry or focal enlargement may indicate cancer.
  • Consistency: Hard or irregular areas (nodules) are suspicious for malignancy, whereas a smooth, elastic texture is more consistent with BPH.
  • Symmetry: Asymmetry or lateralization may warrant further investigation.
  • Tenderness: Pain or discomfort may suggest prostatitis or other inflammatory conditions.

    • Limitations and Complementary Role
    While DRE offers high specificity for detecting palpable abnormalities, its sensitivity for prostate cancer is limited (~30–50%) due to the inability to detect non-palpable lesions. Thus, DRE is most valuable as an adjunct to PSA testing and imaging, particularly in high-risk populations or when clinical suspicion is elevated.

    Interpreting Prostate-Specific Antigen (PSA) Test Results

    The PSA test measures serum levels of prostate-specific antigen, a glycoprotein produced by both malignant and non-malignant prostate tissue. PSA testing is widely used for prostate cancer screening, though its interpretation requires consideration of age-specific reference ranges, PSA velocity, and clinical context to avoid overdiagnosis or unnecessary anxiety.

    Age-Specific Reference Ranges and Red Flags
    PSA levels vary with age due to physiological prostate enlargement (BPH) and other age-related factors. General guidelines include:

  • Age 40–49: PSA < 2.5 ng/mL
  • Age 50–59: PSA < 3.5 ng/mL
  • Age 60–69: PSA < 4.5 ng/mL
  • Age ≥70: PSA < 6.5 ng/mL

    • Key Interpretive Criteria

  • PSA Velocity: An annual PSA increase ≥0.35 ng/mL/year or ≥0.75 ng/mL/year (in older men) is associated with higher cancer risk.
  • PSA Density: PSA level divided by prostate volume (from TRUS) >0.15 ng/mL²/cm³ suggests higher likelihood of cancer.
  • Free PSA Ratio: A free PSA (non-complexed PSA) <10% in men with total PSA 4–10 ng/mL increases suspicion for malignancy.
  • PSA Doubling Time: A PSA doubling time <3 years is strongly indicative of aggressive prostate cancer.

    • Clinical Algorithm for PSA Follow-Up
    For PSA levels between 4–10 ng/mL, repeat testing or additional diagnostics (e.g., mpMRI) are recommended. Levels >10 ng/mL warrant immediate urological evaluation, as the positive predictive value for cancer approaches 50–60%. In asymptomatic men with PSA <4 ng/mL, shared decision-making is advised regarding repeat screening intervals.

    Transrectal Ultrasound (TRUS) and Multiparametric MRI (mpMRI) in Prostate Imaging

    TRUS and mpMRI are advanced imaging modalities used to visualize prostate anatomy and pathology, each with distinct advantages in detecting prostate cancer versus BPH.

    Transrectal Ultrasound (TRUS) Technique
    TRUS involves inserting a high-frequency ultrasound probe into the rectum to generate real-time images of the prostate. Key applications include:

  • Prostate Volume Measurement: Essential for calculating PSA density and guiding biopsy targeting.
  • Guided Biopsy: Used during transrectal or transperineal biopsies to direct needle placement.
  • Cystoscopy Assistance: TRUS may be combined with cystoscopy for simultaneous evaluation of the bladder and urethra.

    • Limitations of TRUS
    TRUS has limited resolution for detecting small or peripheral zone cancers, with sensitivity ~50–70% for clinically significant disease. It is less effective in obese patients or those with large prostates, where image quality may degrade.

    Multiparametric MRI (mpMRI) Protocol
    mpMRI integrates multiple sequences to assess prostate tissue characteristics:
    1. T2-Weighted Imaging: Differentiates between benign and malignant tissue based on signal intensity (cancer appears hypointense).
    2. Diffusion-Weighted Imaging (DWI): Highlights cellular density differences; malignant tissue restricts water diffusion (high signal on apparent diffusion coefficient maps).
    3. Dynamic Contrast-Enhanced (DCE) MRI: Evaluates vascularity; tumors exhibit rapid contrast uptake and washout.

    PI-RADS Scoring System
    The Prostate Imaging Reporting and Data System (PI-RADS) v2.1 classifies lesions on a 1–5 scale, with scores ≥3 prompting further evaluation (e.g., biopsy). mpMRI demonstrates superior sensitivity (~80–90%) and specificity (~70–80%) for clinically significant prostate cancer compared to TRUS.

    Comparative Roles in BPH vs. Prostate Cancer

  • BPH: TRUS is sufficient for volume assessment, while mpMRI is rarely needed unless symptoms are refractory to medical therapy.
  • Prostate Cancer: mpMRI is the gold standard for detecting and localizing cancer, particularly in active surveillance or focal therapy candidates. TRUS remains useful for biopsy guidance but is less informative for staging.

    • Prostate Biopsy Protocol and Post-Procedure Care

    Prostate biopsy is the definitive diagnostic procedure for confirming prostate cancer, involving the acquisition of tissue samples for histopathological analysis. The choice of biopsy technique, sedation, and post-procedure management depends on patient risk, prior imaging findings, and institutional protocols.

    Biopsy Techniques and Needle Types
    1. Transrectal Ultrasound-Guided Biopsy (TRUS-Bx)

  • Procedure: Under TRUS guidance, 10–12 core needle biopsies are obtained from systematic locations (e.g., sextant or extended 12-core patterns).
  • Needle Types: Automated spring-loaded (e.g., 18-gauge) or manual biopsy guns with disposable needles.
  • Targeted Biopsy: Lesions identified on mpMRI are sampled using fusion biopsy (combining MRI and TRUS images) or cognitive biopsy (examiner estimates lesion location).

    • 2. Transperineal Biopsy

  • Indications: Preferred in patients with prior negative biopsies, high suspicion for anterior prostate cancer, or infectious risks (e.g., prostatitis).
  • Advantages: Lower risk of sepsis, better access to anterior lesions, and reduced rectal trauma.

    • Sedation Options

  • Local Anesthesia: Lidocaine gel applied transrectally or perineally for transperineal biopsies.
  • Moderate Sedation: Intravenous midazolam/fentanyl for anxious patients or extended procedures.
  • General Anesthesia: Rarely used unless contraindications to sedation exist (e.g., severe cardiac disease).

    • Post-Procedure Care Instructions

  • Antibiotic Prophylaxis: Fluoroquinolones (e.g., levofloxacin) or trimethoprim-sulfamethoxazole are administered pre- and post-biopsy to reduce infection risk.
  • Post-Biopsy Monitoring: Patients are observed for 1–2 hours for signs of hemorrhage or sepsis (e.g., fever, hypotension).
  • Activity Restrictions: Avoid strenuous activity, sexual intercourse, or bicycle riding for 1–2 weeks to minimize bleeding risk.
  • Follow-Up: PSA levels are rechecked 4–6 weeks post-biopsy to assess for post-biopsy inflammation (which may transiently elevate PSA).

    • Complications and Management

  • Hematuria/Hematochezia: Typically resolves within 1–2 days; persistent bleeding may require catheterization.
  • Infection: Fever or sepsis requires immediate antibiotic adjustment and hospitalization.
  • Pain: Mild discomfort is common; NSAIDs or acetaminophen are recommended.

    • Uroflowmetry and Post-Void Residual (PVR) Measurements in BPH Assessment

    Uroflowmetry and PVR measurements are non-invasive, functional tests used to evaluate lower

    The prostate, though often overlooked until symptoms arise, serves as a cornerstone of male physiological function and a critical area for medical vigilance. From its foundational role in semen composition to its susceptibility to age-related changes, the gland exemplifies the delicate balance between normal aging and pathological progression. Diagnostic advancements—such as multiparametric MRI and PSA velocity tracking—have refined early detection, while lifestyle modifications and targeted therapies offer pathways to mitigate risks. As research continues to unravel the genetic and environmental factors influencing prostate health, one truth remains clear: awareness, timely evaluation, and personalized management are essential to navigating the complexities of this vital organ. By prioritizing education and proactive health strategies, individuals can safeguard their prostate’s function and maintain optimal well-being throughout their lives.

    FAQ

    What is the prostate and what does it do?

    The prostate is a small, walnut-sized gland in men that produces fluid for semen, helping to nourish and transport sperm during ejaculation. It surrounds the urethra and plays a key role in urinary and reproductive function.

    What does the prostate do?

    The prostate produces a milky fluid that makes up part of semen, providing nutrients and protection for sperm. It also helps propel semen during ejaculation and supports urinary control.

    What is the prostate used for?

    The prostate’s main function is to produce seminal fluid, which mixes with sperm to create semen. It also regulates the release of urine and semen through the urethra.

    What is the prostate gland?

    The prostate gland is an exocrine gland in males located below the bladder, surrounding the urethra. It secretes fluid that enhances sperm motility and longevity in semen.

    What is prostate cancer?

    Prostate cancer is a malignant growth that develops in the prostate gland, often growing slowly but potentially becoming aggressive. It’s the most common cancer in men and may require treatment depending on its stage and symptoms.

    What is a normal prostate size or number supposed to be?

    A healthy adult male prostate typically measures about 2–4 cm in width, 3–5 cm in length, and 2–3 cm in height. Size can vary with age, but significant enlargement (e.g., >30 mL) may indicate benign prostatic hyperplasia (BPH).